Final Results for 13 months to 31 December 2019
RNS & Investor News
Exclusive licence agreement for OptiBiome® with OptiPharm Pty Ltd.
31 March 2020
OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has entered into an exclusive licence agreement for the use of its OptiBiome® weight management ingredient with OptiPharm Pty Ltd. ("OptiPharm").
OptiBiotix registered OptiBiome® as an alternative trademark to SlimBiome® to support the sale of its SlimBiome® ingredient in countries in which an implied health claim cannot be made (e.g. Thailand). The terms of this exclusive licence agreement grant OptiPharm exclusive use of the OptiBiome® trademark in over 20 markets including Australia, parts of Asia, New Zealand, Middle East, Gulf States and North America. Market exclusivity is linked to minimum order quantities.
OptiPharm (https://www.optipharm.com) is a privately owned Australian company currently in its 24th year of operation. OptiPharm specialises in weight management, nutrition and infant formula and their products are produced in state of the art Australian manufacturing facilities that are GMP qualified and HACCP certified (a risk based system which introduces controls at critical points of the manufacturing process).
OptiPharm's flagship brand, Optislim, is the No. 1 Australian weight management brand incorporating shakes, soups and bars available as Total (Very Low Calorie Diet) or Partial (Low Calorie Diet) Meal Replacements. Optislim is enjoyed by consumers throughout Australia, New Zealand, China, shortly the Middle East and the UAE, and is poised for release throughout South East Asia and North America. Company-owned trademarked brands include:
- Optislim™ - (weight management meal replacements, including shakes, chocolate bars & soups) www.optislim.com.au
- isustain™ - (nutritional meal replacements for Adults, Children & Diabetics) www.isustain.net.au
- OPTI GOLD™ - (infant formula) www.optigold.com.au
Garry McDonald, Managing Director of OptiPharm, commented: "We are delighted to have completed negotiations with OptiBiotix for access to their patented ingredient OptiBiome® for exclusive use in over 20 markets globally. In these troubling times & with clinical research identifying a link between excess weight and one's immune system, OptiPharm are continually searching for innovative ingredients such as OptiBiome®, to enhance our Optislim product formulations. We look forward to working with OptiBiotix to deliver to our customers the latest in innovation, value and quality."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to enter into a commercial agreement with OptiPharm to make OptiBiotix's award-winning weight management solution available to a wide range of customers through major pharmacy and supermarket retailers and online in over 20 countries. We are excited to work with such a well known market leading partner who has the means to promote its products aggressively (https://www.soccerex.com/insight/articles/2016/melbourne-victory-net-optislim-deal). This deal further expands our access to global markets and we are particularly pleased to have our functional ingredient sold by major retailers in more and more countries around the world creating value for our partners, customers and shareholders. "
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
|OptiBiotix Health plc||www.optibiotix.com|
|Stephen O'Hara, Chief Executive||Contact via Walbrook below|
|Cairn Financial Advisers LLP (NOMAD)||Tel: 020 7213 0880|
|Liam Murray / Jo Turner / Ludovico Lazzaretti|
|finnCap (Broker)||Tel: 020 7220 0500|
|Geoff Nash / Kate Bannatyne (Corporate Finance)|
|Camille Gochez (Corporate Broking)|
|goetzpartners securities Limited||Tel: 0203 859 7725|
|Walbrook PR Ltd||Mob: 07876 741 001|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020